MAZZIOTTI, Gherardo
 Distribuzione geografica
Continente #
NA - Nord America 5.451
EU - Europa 1.125
AS - Asia 572
AF - Africa 171
SA - Sud America 15
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.343
Nazione #
US - Stati Uniti d'America 5.430
SG - Singapore 322
FI - Finlandia 316
IE - Irlanda 227
CN - Cina 175
NG - Nigeria 167
IT - Italia 125
FR - Francia 122
DE - Germania 102
NL - Olanda 66
GB - Regno Unito 46
SE - Svezia 29
IN - India 24
BE - Belgio 20
MK - Macedonia 16
RU - Federazione Russa 16
CA - Canada 15
PK - Pakistan 13
IL - Israele 10
CL - Cile 9
CH - Svizzera 7
ES - Italia 6
PA - Panama 6
PH - Filippine 6
AU - Australia 5
IR - Iran 5
KR - Corea 5
UA - Ucraina 5
GR - Grecia 4
JP - Giappone 4
CZ - Repubblica Ceca 3
HU - Ungheria 3
PL - Polonia 3
TR - Turchia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AR - Argentina 2
BG - Bulgaria 2
BR - Brasile 2
NZ - Nuova Zelanda 2
RO - Romania 2
AT - Austria 1
BD - Bangladesh 1
CI - Costa d'Avorio 1
IQ - Iraq 1
KE - Kenya 1
LU - Lussemburgo 1
MD - Moldavia 1
MY - Malesia 1
PE - Perù 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
UG - Uganda 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 7.343
Città #
Chandler 1.194
Wilmington 1.088
San Mateo 388
Helsinki 316
Ann Arbor 262
Dublin 227
Singapore 215
Boardman 205
Lawrence 187
Princeton 187
Leawood 180
Benin City 167
New York 165
Shanghai 161
Paris 114
Fairfield 94
Woodbridge 81
Ashburn 80
Amsterdam 55
Seattle 38
London 34
Milan 29
San Diego 27
Santa Clara 21
Brussels 20
Norwalk 19
Los Angeles 17
Abbiategrasso 13
Lahore 13
Monmouth Junction 12
Pune 12
Redmond 12
Toronto 11
Phoenix 10
Skopje 8
Shenzhen 7
Mumbai 6
Bitola 5
Des Moines 5
Frankfurt am Main 5
Madrid 5
Seoul 5
Falkenstein 4
Houston 4
Meppel 4
Ardabil 3
Budapest 3
Clearwater 3
Kocaeli 3
Kolkata 3
Novokuznetsk 3
Olongapo City 3
Prilep 3
Redwood City 3
Rome 3
Athens 2
Augusta 2
Brno 2
Buenos Aires 2
Cesano Boscone 2
Chieti 2
Dronten 2
Erbusco 2
Florence 2
Gdansk 2
Geneva 2
Gunzenhausen 2
Larissa 2
Las Pinas 2
Newark 2
Nuremberg 2
Omaha 2
Palazzolo sull'Oglio 2
Sale Marasino 2
San Francisco 2
Tokyo 2
Turi 2
Venegono Superiore 2
Yuncheng 2
Abidjan 1
Adelaide 1
Agrate Brianza 1
Andover 1
Auckland 1
Bratislava 1
Bristol 1
Bruttisellen 1
Büdelsdorf 1
Cagayan de Oro 1
Calgary 1
Cambridge 1
Canberra 1
Cape Town 1
Charlotte 1
Chisinau 1
Cincinnati 1
Council Bluffs 1
Dearborn 1
Durham 1
Eden Prairie 1
Totale 5.811
Nome #
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study 123
Pituitary Diseases and Bone 64
Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines 64
Acromegalic osteopathy 63
Pituitary Diseases and Bone 60
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. 57
Biological activity of activating thyrotrophin receptor mutants: modulation by iodide 56
Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha 54
Association between L-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism 54
Active acromegaly enhances spontaneous parathyroid hormone pulsatility 53
Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs 52
Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation 52
Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis 51
High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma 51
Abdominal Aortic Calcification as a Marker of Relationship Between Atherosclerosis and Skeletal Fragility 51
New understanding and treatments for osteoporosis 50
Bone disorders associated with acromegaly: mechanisms and treatment 50
Tear thyrotropin receptor stimulator in normal smokers and thyroid eye disease patients 50
Biochemical Evaluation of Patients with Active Acromegaly and Type 2 Diabetes Mellitus: Efficacy and Safety of the Galanin Test 50
GH receptor isoforms and skeletal fragility in acromegaly 50
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly 50
High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma (vol 2, pg 1089, 2018) 49
Bone and Joint Disorders in Acromegaly 48
Cardiovascular risk in aging and obesity: Is there a role for GH? 48
Bone safety of dual-release hydrocortisone in patients with hypopituitarism 48
Medullary thyroid carcinoma treated with percutaneous ultrasound-guided radiofrequency ablation 48
The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism 47
Artificial intelligence-based radiomics on computed tomography of lumbar spine in subjects with fragility vertebral fractures 46
Insulin and GH-IGF-I axis: endocrine pacer or endocrine disruptor? 46
Autoimmune thyroiditis after elimination of iodine deficiency in Sri Lanka 46
High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures 46
Influence of diabetes mellitus on vertebral fractures in men with acromegaly 46
Glucocorticoid-induced osteoporosis: Clinical and therapeutic aspects 45
Type-1 response in peripheral CD4(+) and CD8(+) T cells from patients with Hashimoto's thyroiditis 44
Parathyroid hormone pulsatility: physiological and clinical aspects 44
Prevalence of Vertebral Fractures in Men with Acromegaly 44
The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. 44
HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway 44
Current and Emerging Aspects of Diabetes Mellitus in Acromegaly 44
Resistance to somatostatin analogs in acromegaly: An evolving concept? 43
Treatment of hypothyroidism: all that glitters is gold? 43
Effects of Recombinant Follicle-Stimulating Hormone on Bone Turnover Markers in Infertile Women Undergoing in Vitro Fertilization Procedure 43
Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: A prospective study 43
High bone marrow fat in patients with Cushing's syndrome and vertebral fractures. 43
Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles 42
Current and future medical treatments for patients with acromegaly 42
Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors 42
High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas 42
Lack of association between changes in plasma leptin concentration and in food intake during the menstrual cycle 42
Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency 42
An improved polymerase chain reaction (PCR) protocol for unambiguous detection of growth hormone gene deletions 42
Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies 42
Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis 42
Long-term effects of lanreotide SR and octreotide LAR (R) on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly 42
Growth hormone, insulin-like growth factors, and the skeleton 41
Octreotide for acromegaly treatment: a reappraisal 41
Insulin resistance and advancing age: What role for dehydroepiandrosterone sulfate? 41
High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study 41
Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience 41
Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect 40
Diabetes in Cushing syndrome: basic and clinical aspects 40
Glucocorticoid-induced osteoporosis: pathophysiology and therapy 40
Thyroid Autoimmunity 40
Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study 40
High prevalence of radiological vertebral fractures in adult patients with Ehlers-Danlos syndrome 40
Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure 40
Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis - A prospective study 40
Thyrotoxicosis in patients with COVID-19: the THYRCOV study 40
Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment 40
Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly 39
Growth hormone deficiency in treated acromegaly and active Cushing's syndrome 39
Is the IFN-alpha-related thyroid autoimmunity an immunologically heterogeneous disease? 39
Oxford Textbook of Endocrinology and Diabetes, 3rd Edition 39
Low testosterone predicts hypoxemic respiratory insufficiency and mortality in patients with COVID-19 disease: another piece in the COVID puzzle 39
Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density 39
Glucocorticoid-induced osteoporosis and parathyroid hormone. 38
Eight parathyroid glands incidentally discovered during a surgical intervention for secondary hyperparathyroidism: An unusual clinical finding 38
Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects 38
Growth hormone replacement therapy and fracture risk 38
Diabetes in Cushing Disease. 38
Glucocorticoid-induced osteoporosis: an update 38
Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism 38
Diabetes insipidus and increased serum levels of leptin and lactate-dehydrogenase (LDH) in an adolescent boy with a primary intracranial germinoma. Case Report and an endocrinological revaluation of literature 38
MANAGEMENT OF ENDOCRINE DISEASE Therapeutics of vitamin D 38
Recombinant growth hormone (GH) therapy in GH-deficient adults: A long-term controlled study on daily versus thrice weekly injections 38
Diagnosis and treatment of acromegaly and its complications: consensus guidelines. 38
The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are needed 38
In memoriam: Dr. Irene Claudia Floriani (1964-2016) 38
Primary hyperparathyroidism in prostate cancer: guilty or not guilty? 37
Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines 37
Growth hormone deficiency in the adult 37
Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis under treatment with denosumab: a real-life observational study. 37
Cortisol and the muscle-bone axis: response to comments by Molfino et al. 37
Effects of increased thyroxine dosage pre-conception on thyroid function during early pregnancy 37
High prevalence of radiological vertebral fractures in HIV-infected males 37
Long-term treatment with interferon-β therapy for multiple sclerosis and occurrence of Graves' disease 37
Reevaluating thyrotropin receptor-induced mouse models of Graves' disease and ophthalmopathy 36
Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects 36
Increased prevalence of radiological spinal deformities in active acromegaly: A cross-sectional study in postmenopausal women 36
SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study. 36
Totale 4.440
Categoria #
all - tutte 59.597
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.597


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201 0 0 0 0 0 0 0 0 0 0 0 1
2020/20211.847 5 5 7 14 17 583 251 123 425 227 3 187
2021/2022903 75 5 7 221 0 4 16 140 83 100 178 74
2022/20233.011 408 126 265 337 309 290 13 262 505 255 194 47
2023/20241.650 129 198 314 95 47 185 86 94 46 28 159 269
2024/202584 72 12 0 0 0 0 0 0 0 0 0 0
Totale 7.496